Breaking tolerance: an update of Treg dysfunction in autoimmunity.

Trends Immunol

Yale School of Medicine, 300 George St, New Haven, CT 06511, USA. Electronic address:

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

FOXP3 regulatory T cells (Tregs) are essential for maintaining immune tolerance, and their dysfunction is a hallmark of autoimmune diseases. Recent studies have identified key transcriptional, metabolic, and environmental drivers of Treg instability and loss of function. Understanding these mechanisms opens new avenues for therapeutic interventions aimed at restoring immune homeostasis in autoimmunity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2025.06.007DOI Listing

Publication Analysis

Top Keywords

breaking tolerance
4
tolerance update
4
update treg
4
treg dysfunction
4
dysfunction autoimmunity
4
autoimmunity foxp3
4
foxp3 regulatory
4
regulatory cells
4
cells tregs
4
tregs essential
4

Similar Publications

PurposeTo evaluate the safety and ability of an ophthalmic solution containing Poloxamer 407 and Polyquaternium 133 to reduce conjunctival bacterial load before cataract surgery.MethodsPatients (n = 74) were randomized to 2 groups: treatment (n = 37) or placebo (treatment's vehicle; (n = 37)) BID from V1 to V3. Patients were also given standard postoperative treatment from V2 to V3.

View Article and Find Full Text PDF

Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care.

View Article and Find Full Text PDF

Background: Patients with BRAF wild type (wt) metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICI) face a poor prognosis. Chemotherapy has been shown to induce genetic mutations, modify the tumor microenvironment and microbiome, and influence immune system activity.

Objectives: This prospective multicenter phase II trial investigates whether two applications of an alkylating agent (dacarbazine/DTIC) can sensitize ICI non-responsive patients with metastatic melanoma to the same checkpoint inhibitor regime.

View Article and Find Full Text PDF

Endocrine therapies for breast cancer (BC) (i.e., selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AI)) lower the risk for cancer recurrence but are linked to an increased risk of type 2 diabetes (T2D).

View Article and Find Full Text PDF

Fe-incorporated hydrogels are particularly valuable for wearable devices due to their tunable mechanical properties and ionic conductivity. However, conventional immersion-based fabrication fundamentally limits hydrogel performance because of heterogeneous ion distribution, ionic leaching, and scalability limitations. To overcome these challenges, we report a novel one-pot strategy where controlled amounts of Fe are directly added to polyacrylamide-sodium acrylate (PAM-SA) precursor solutions, ensuring homogeneous ion distribution.

View Article and Find Full Text PDF